日本語English简体中文 繁體中文

4563 AnGes,Inc.アンジェスTSE Growth / Pharmaceuticals

0 posts

AnGes,Inc. (4563) at a glance

Code
4563
Company
AnGes,Inc.
Local name
アンジェス
Market
TSE Growth
Sector
Pharmaceuticals
Share price
¥24.0 -1.00 (-4.00%) Nov 20 close

Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.

AnGes,Inc. (4563) Stock Price HistoryNear an all-time low

AnGes,Inc. closed at ¥24.0 on Nov 20, 2026, −17.2% over 1 month, −68.0% over 1 year.

2026-11-13 営業外収益、営業外費用、特別利益、特別損失並びに法人税等調整額の計上及び業績予… / 2026年12月期第3四半期決算短信〔日本基準〕(連結)¥30.0¥24.0Oct 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
1-Month High¥30.0Oct 21
1-Month Low¥24.0Nov 17
1-Week Change−11.1%vs Nov 13
1-Month Change−17.2%vs Oct 20

If you had invested ¥100,000 1 month ago, it would be worth ¥82,759 today (−17.2%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −11.9%, while this stock moved −17.2%.

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥24.0−1−4.00%
Nov 19 (Thu)¥25.0+0+0.00%
Nov 18 (Wed)¥25.0+1+4.17%
Nov 17 (Tue)¥24.0−1−4.00%
Nov 16 (Mon)¥25.0−2−7.41%
Nov 13 (Fri)¥27.0+1+3.85%
Nov 12 (Thu)¥26.0−1−3.70%
Nov 11 (Wed)¥27.0+1+3.85%
Nov 10 (Tue)¥26.0−1−3.70%
Nov 9 (Mon)¥27.0+2+8.00%
2026-09-15 第46回新株予約権(行使価額修正条項付)の取得及び消却の完了に関するお知らせ2026-11-13 営業外収益、営業外費用、特別利益、特別損失並びに法人税等調整額の計上及び業績予… / 2026年12月期第3四半期決算短信〔日本基準〕(連結)¥42.0¥24.0Aug 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
3-Month High¥42.0Aug 20
3-Month Low¥24.0Nov 17
1-Month Change−17.2%vs Oct 20
3-Month Change−42.9%vs Aug 20

If you had invested ¥100,000 3 months ago, it would be worth ¥57,143 today (−42.9%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −14.8%, while this stock moved −42.9%.

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥24.0−1−4.00%
Nov 19 (Thu)¥25.0+0+0.00%
Nov 18 (Wed)¥25.0+1+4.17%
Nov 17 (Tue)¥24.0−1−4.00%
Nov 16 (Mon)¥25.0−2−7.41%
Nov 13 (Fri)¥27.0+1+3.85%
Nov 12 (Thu)¥26.0−1−3.70%
Nov 11 (Wed)¥27.0+1+3.85%
Nov 10 (Tue)¥26.0−1−3.70%
Nov 9 (Mon)¥27.0+2+8.00%
2026-09-15 第46回新株予約権(行使価額修正条項付)の取得及び消却の完了に関するお知らせ2026-11-13 営業外収益、営業外費用、特別利益、特別損失並びに法人税等調整額の計上及び業績予… / 2026年12月期第3四半期決算短信〔日本基準〕(連結)¥52.0¥24.0May 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
6-Month High¥52.0Jul 7
6-Month Low¥24.0Nov 17
3-Month Change−42.9%vs Aug 20
6-Month Change−51.0%vs May 20

If you had invested ¥100,000 6 months ago, it would be worth ¥48,980 today (−51.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −5.6%, while this stock moved −51.0%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥24.0−17.2%
Oct 2026¥29.0−23.7%
Sep 2026¥38.0−2.6%
Aug 2026¥39.0−17.0%
Jul 2026¥47.0+0.0%
Jun 2026¥47.0−4.1%
May 2026¥49.0−5.8%
2026-09-15 第46回新株予約権(行使価額修正条項付)の取得及び消却の完了に関するお知らせ2026-11-13 営業外収益、営業外費用、特別利益、特別損失並びに法人税等調整額の計上及び業績予… / 2026年12月期第3四半期決算短信〔日本基準〕(連結)¥75.0¥24.0Nov 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
52-Week High¥75.0Nov 20
52-Week Low¥24.0Nov 17
Year to Date−60.7%vs Dec 30
From 52-Week High−68.0%Nov 20

If you had invested ¥100,000 1 year ago, it would be worth ¥32,000 today (−68.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +13.3%, while this stock moved −68.0%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥24.0−17.2%
Oct 2026¥29.0−23.7%
Sep 2026¥38.0−2.6%
Aug 2026¥39.0−17.0%
Jul 2026¥47.0+0.0%
Jun 2026¥47.0−4.1%
May 2026¥49.0−5.8%
Apr 2026¥52.0−8.8%
Mar 2026¥57.0−3.4%
Feb 2026¥59.0−1.7%
Jan 2026¥60.0−1.6%
Dec 2025¥61.0−17.6%
Nov 2025¥74.0―
¥103¥24.0Nov 20, 2023Nov 20, 2026
Price13-week MA26-week MANikkei 225
3-Year High¥103Aug 25, 2025
3-Year Low¥24.0Nov 20, 2026
Annualized Return−34.4%
Max Drawdown−76.7%

If you had invested ¥100,000 3 years ago, it would be worth ¥28,235 today (−71.8%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +67.8%, while this stock moved −71.8%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥24.0−60.7%
2025¥61.0―
¥424¥24.0Nov 22, 2021Nov 20, 2026
Price13-week MA26-week MANikkei 225
5-Year High¥424Nov 22, 2021
5-Year Low¥24.0Nov 20, 2026
Annualized Return−43.7%
Max Drawdown−94.3%

If you had invested ¥100,000 5 years ago, it would be worth ¥5,660 today (−94.3%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +96.3%, while this stock moved −94.3%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥24.0−60.7%
2025¥61.0―
¥3,824¥24.0Oct 1, 2002Nov 20, 2026
Price1-year MA2-year MANikkei 225
All-Time High¥3,824Nov 2003
All-Time Low¥24.0Nov 2026
Total Change−98.7%vs Oct 2002
Annualized Return−16.3%

If you had invested ¥100,000 in Oct 2002, it would be worth ¥1,345 today (−98.7%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +557.9%, while this stock moved −98.7%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥24.0−60.7%
2025¥61.0+15.1%
2024¥53.0−26.4%
2023¥72.0−41.0%
2022¥122−68.2%
2021¥384−69.2%
2020¥1,245+94.8%
2019¥639+76.0%
2018¥363−41.4%
2017¥619+147.6%
2016¥250+8.7%
2015¥230−37.8%
2014¥370−29.3%
2013¥523+130.7%
2012¥227+20.8%
2011¥188−61.4%
2010¥487−18.5%
2009¥598+5.7%
2008¥566−78.5%
2007¥2,628+1.8%
2006¥2,582−27.0%
2005¥3,535+57.7%
2004¥2,243−35.3%
2003¥3,468+79.8%
2002¥1,929―

Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Oct 2002). Please check the latest prices before trading.

AnGes,Inc. (4563) financial indicators

PBR
75.97
ROE
-8,157.13%
Dividend yield
0.00%

See all financial indicators for AnGes,Inc. (market cap, DOE, equity ratio, EV, EBITDA, ROIC and more)

PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.

Key features of AnGes,Inc. (4563)

Business overview

Together with three consolidated subsidiaries, the company develops and sells pharmaceuticals centered on gene-based medicines, and also provides contract testing services centered on screening for rare genetic diseases. The company handles R&D and sales of gene therapy products, nucleic acid drugs and more and contract testing, and its US subsidiary AnGes USA, Inc. handles drug development in the United States. Subsidiary EmendoBio Inc. is advancing R&D in the United States of genome editing products that could treat diseases with no previous treatment, with research and development carried out by a subsidiary in Israel. Since the probability of bringing a new drug to market from a candidate compound is said to be about 1 in 30,000 and development often takes more than 10 years, its business structure has R&D costs coming first. In April 2021 it opened a testing facility and takes on screening tests for rare genetic diseases from local governments and medical institutions.

Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.

Position within Pharmaceuticals (79 companies)

PBR75.97xAbove the sector median of 1.86x (No. 76 from the lowest)
ROE-8,157.13%No. 54 in the sector (highest first); median 4.17%
Market cap¥9.6 bnNo. 46 in the sector (largest first)

Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.

Price milestones

52-week high¥752025/11/20
52-week low¥2411/20
Current position0.0%Where the low is 0% and the high is 100% (close on 11/20: ¥24)
Year to date-60.7%No. 75 of 77 in the sector (best first)
1 year-68.0%

Based on closing prices (adjusted for stock splits, excluding dividends).

Kabutaro's ranking history

Top 50 losers3 timesLatest: 11/10 (No. 46)

Gainers and losers have been recorded since 9/2026.

Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.

Recent disclosures (TDnet, in Japanese)

Filings from the past 12 months (8).

Posts

This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.

No posts yet. Be the first to write something.

Write on the AnGes,Inc. board

You will need this to delete your post. Please keep it safe.
By posting you agree to the board rules (Japanese). You are responsible for what you write.

More Japanese stocks in English

Japanese Stock Message Board: stocks available in English

Other boards in English